FDA Grants Fast Track Status to Tesaro’s Niraparib for Ovarian, Other Cancers

FDA Grants Fast Track Status to Tesaro’s Niraparib for Ovarian, Other Cancers
Tesaro has received fast track designation from the U.S. Food and Drug Administration (FDA) for the use of niraparib in patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. The FDA’s fast track program will facilitate niraparib’s development and expedite review to address highly unmet medical needs. As part of the fast track program,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Harsh says:

    Hi,
    Can anybody suggest if this drug will be useful in Platinum resistant Ovarian Cancer patients as well.
    Was that also the part of the study?
    Thanks,
    Harsh

Leave a Comment

Your email address will not be published. Required fields are marked *